Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2013 Jun 18:6:40.
doi: 10.1186/1756-8722-6-40.

Novel agents and biomarkers for acute lymphoid leukemia

Yanmin Zhao  1 , He Huang, Guoqing Wei
Affiliations
Review

Novel agents and biomarkers for acute lymphoid leukemia

Yanmin Zhao et al. J Hematol Oncol. .

Abstract

New genetic markers for adult acute lymphoblastic leukemia (ALL) have been found to have prognostic impact, such as the lymphoid transcription factor gene IKZF1 alterations, which are associated with a high rate of leukemic relapse in B-ALL. Although complete remission rates by induction chemotherapy in ALL are now high, the long-term survival is still disappointing. Improvements in the survival outcome of ALL have been observed in young adults as a result of the use of pediatric inspired regimens and the broadening of the number of patients who are eligible for allogeneic SCT. Development of new and less toxic agents also provide promise to improve the outcome in adult ALL, such as tyrosine kinase inhibitors in Ph-positive ALL, rituximab in CD20-positive disease, blinatumomab in precursor B-ALL and nelarabine in T-lineage ALL. Challenges for the future are to implement genomic profiling into the clinical setting to guide risk stratification and providing novel targets for tailored therapies.

PubMed Disclaimer

References

    1. Pui CH, Pei D, Sandlund JT, Ribeiro RC, Rubnitz JE, Raimondi SC, Onciu M, Campana D, Kun LE, Jeha S. et al. Long-term results of St Jude total therapy studies 11, 12, 13A, 13B, and 14 for childhood acute lymphoblastic leukemia. Leukemia. 2010;24(2):371–382. doi: 10.1038/leu.2009.252. - DOI - PMC - PubMed
    1. Bassan R. Evolving strategies for the management of high-risk adult acute lymphoblastic leukemia. Haematologica. 2005;90(10):1299. - PubMed
    1. Pullarkat V, Slovak ML, Kopecky KJ, Forman SJ, Appelbaum FR. Impact of cytogenetics on the outcome of adult acute lymphoblastic leukemia: results of Southwest Oncology Group 9400 study. Blood. 2008;111(5):2563–2572. doi: 10.1182/blood-2007-10-116186. - DOI - PMC - PubMed
    1. Sirop SJ A-KA, Begna K, Gangat N, Letendre L, Porrata LF. et al. Lack of prognostic significance of monosomal karyotype and absolute lymphocyte count at diagnosis in Philadelphia chromosome negative acute lymphoblastic leukemia. Blood (ASH Annual Meeting Abstracts) 2012;120:1476.
    1. Nagafuji K, Miyamoto T, Eto T, Kamimura T, Taniguchi S, Okamura T, Ohtsuka E, Yoshida T, Higuchi M, Yoshimoto G. et al. Monitoring of minimal residual disease (MRD) is useful to predict prognosis of adult patients with Ph-negative ALL: results of a prospective study (ALL MRD2002 Study) J Hematol Oncol. 2013;6:14. doi: 10.1186/1756-8722-6-14. - DOI - PMC - PubMed

MeSH terms

Substances